Australia markets close in 4 hours 4 minutes

ImmunoGen, Inc. (IMGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.77+0.60 (+9.72%)
At close: 04:00PM EST
6.75 -0.02 (-0.30%)
After hours: 07:59PM EST

ImmunoGen, Inc.

830 Winter Street
Waltham, MA 02451-1477
United States
781 895 0600

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 79

Key executives

NameTitlePayExercisedYear born
Mr. Mark Joseph EnyedyPres, CEO & Director1.21MN/A1964
Ms. Susan Altschuller Ph.D.Sr. VP & CFO391.21kN/A1982
Dr. Theresa G. WingroveSr. VP of Regulatory Affairs & Quality548.21kN/A1958
Dr. Anna BerkenblitSr. VP & Chief Medical Officer641.74kN/A1970
Ms. Stacy A. CoenSr. VP & Chief Bus. Officer388.97kN/A1971
Ms. Renee LentiniVP of Fin., Principal Accounting Officer & Corp. ControllerN/AN/A1978
Dr. Thomas RyllSr. VP of Technical OperationsN/AN/A1961
Ms. Courtney O'KonekSr. Director of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Audrey BerganVP & Chief HR OfficerN/AN/AN/A
Ms. Kristen Harrington-SmithSr. VP & Chief Commercial OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Corporate governance

ImmunoGen, Inc.’s ISS governance QualityScore as of 26 September 2021 is 5. The pillar scores are Audit: 6; Board: 5; Shareholder rights: 5; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.